Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Kardiovaskulære effekter av angiotensin-(1-7) ved fedmehypertensjon

21. september 2026 oppdatert av: Amy Arnold, Milton S. Hershey Medical Center

Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

A randomized, double blind, placebo controlled, crossover study will be conducted to determine if acute intravenous angiotensin-(1-7) infusion reduces cardiovascular sympathetic tone and blood pressure and improves the function of blood vessels in participants with obesity hypertension. This is an outpatient study that requires a screening visit, and if eligible, two study visits separated by at least one week in the Clinical Research Center within the Penn State Milton S. Hershey Medical Center. The study visits will include intravenous infusion of angiotensin-(1-7) or saline for approximately two hours, starting with increasing doses and holding at a steady-state dose. Endothelial function will be measured and blood samples collected at baseline and at the end of infusion. Blood pressure, heart rate, and muscle sympathetic nerve activity (via microneurography) will be measured continuously throughout the study. Each study visit will last approximately 4 hours.

Studietype

Intervensjonell

Registrering (Antatt)

52

Fase

  • Tidlig fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Pennsylvania
      • Hershey, Pennsylvania, Forente stater, 17033
        • Rekruttering
        • Penn State Milton S. Hershey Medical Center
        • Underetterforsker:
          • Urs A Leuenberger, MD
        • Underetterforsker:
          • Aimee Cauffman, RN
        • Underetterforsker:
          • Cheryl Blaha, RN
        • Underetterforsker:
          • Jian Cui, PhD
        • Ta kontakt med:
        • Underetterforsker:
          • Takuto Hamaoka, MD, PhD
        • Underetterforsker:
          • Mami Hamaoka, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Men and women of all races
  • Age 18 to 65 years
  • Body mass index (BMI) between 30-45 kg/m2
  • Pre-hypertension (defined as two or more seated blood pressure readings >120/80 mmHg) or hypertension (defined as two or more seated blood pressure readings >130/80 mmHg or use of antihypertensive medications)
  • Capable of giving informed consent
  • Fluent in written and spoken English
  • Satisfactory history and physical exam

Exclusion Criteria:

  • Age ≤ 17 or ≥ 66 years
  • Taking more than two antihypertensive medications
  • Secondary causes of hypertension (e.g., pheochromocytoma, primary aldosteronism, aortic coarctation, adrenal disease)
  • Pregnant or nursing women
  • Women taking hormone replacement therapy within 6 months
  • Decisional impairment
  • Prisoners
  • Alcohol or drug abuse
  • Current smokers
  • Highly trained athletes
  • Subjects with >5% weight change in the past 3 months
  • BMI > 45 kg/m2
  • Evidence of type I or type II diabetes (fasting glucose > 126 mg/dL or use of anti-diabetic medications)
  • History of serious cardiovascular disease (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack)
  • History or presence of immunological or hematological disorders
  • Impaired hepatic function [aspartate aminotransferase (AST) or alanine transaminase (ALT) levels >2 times upper limit of normal range]
  • Impaired renal function (serum creatinine >2.0 mg/dl)
  • Anemia
  • Treatment with drugs increasing sympathetic activity [e.g., serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors, stimulants]
  • Treatment with phosphodiesterase-5 inhibitors
  • Treatment with anticoagulants (e.g. warfarin)
  • Treatment with chronic systemic glucocorticoid therapy (>7 consecutive days in 1 month)
  • Treatment with any investigational drug in the 1-month preceding the study
  • Inability to give, or withdraw, informed consent

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Angiotensin-(1-7)

Participants will receive intravenous angiotensin-(1-7) at one study visit for a total of 120 minutes. Angiotensin-(1-7) will be given in escalating doses of 2 ng/kg/min, 4 ng/kg/min, and 8 ng/kg/min. Each of these doses will be infused for 10 minutes. Following this 30 minute dose escalation period, angiotensin-(1-7) will be given at 8 ng/kg/min for an additional 90 minutes. Infusion rates will be calculated for each patient based on body mass.

This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.

Andre navn:
  • Angiotensin I/II (1-7) Acetat
Placebo komparator: Saline

Participants receive intravenous saline at one study visit for a total of 120 minutes. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each patient based on body mass.

Saline will be used as the placebo comparator.

Andre navn:
  • Vanlig saltvann
  • 0,9% natriumklorid

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Muscle Sympathetic Nerve Burst Rate
Tidsramme: 120 minutes

Muscle sympathetic nerve burst rate will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion.

120 minutes
Change in Brachial Artery Diameter
Tidsramme: 120 minutes

A blood pressure cuff will be inflated to a suprasystolic pressure for 5 minutes then deflated. Brachial artery diameter will be measured continuously before, during, and after cuff inflation using duplex ultrasound at baseline and at the end of angiotensin-(1-7) versus saline infusion.

120 minutes

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Muscle Sympathetic Nerve Burst Incidence
Tidsramme: 120 minutes

Muscle sympathetic nerve burst incidence will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion.

120 minutes
Change in Muscle Sympathetic Nerve Amplitude
Tidsramme: 120 minutes

Muscle sympathetic nerve amplitude will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion.

120 minutes
Change in Muscle Sympathetic Nerve Total Activity
Tidsramme: 120 minutes

Muscle sympathetic nerve total activity will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion.

120 minutes
Change in Systolic Blood Pressure
Tidsramme: 120 minutes

Blood pressure will be measured continuously with a finger and arm cuff during angiotensin-(1-7) versus saline infusion.

120 minutes
Change in Diastolic Blood Pressure
Tidsramme: 120 minutes

Blood pressure will be measured continuously with a finger and arm cuff during angiotensin-(1-7) versus saline infusion.

120 minutes
Change in Heart Rate
Tidsramme: 120 minutes

Heart rate will be measured continuously by electrocardiogram during angiotensin-(1-7) versus saline infusion.

120 minutes
Change in Plasma Catecholamines
Tidsramme: 120 minutes

Circulating catecholamine levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion.

120 minutes

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Angiotensin II
Tidsramme: 120 minutes

Plasma angiotensin II levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion.

120 minutes
Change in Angiotensin-(1-7)
Tidsramme: 120 minutes

Plasma angiotensin-(1-7) levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion.

120 minutes
Change in Renin Activity
Tidsramme: 120 minutes

Plasma renin activity will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion.

120 minutes
Change in Aldosterone
Tidsramme: 120 minutes

Plasma or serum aldosterone levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion.

120 minutes
Change in Heart Rate Variability
Tidsramme: 120 minutes

Heart rate variability will be calculated from the continuous electrocardiogram recordings obtained during angiotensin-(1-7) versus saline infusion.

120 minutes
Change in Baroreflex Sensitivity
Tidsramme: 120 minutes

Baroreflex sensitivity will be calculated from the continuous blood pressure and electrocardiogram recordings obtained during angiotensin-(1-7) versus saline infusion.

120 minutes

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Amy Arnold, PhD, Pennsylvania State University College of Medicine

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

23. januar 2025

Primær fullføring (Antatt)

1. mars 2029

Studiet fullført (Antatt)

1. mars 2029

Datoer for studieregistrering

Først innsendt

26. juni 2024

Først innsendt som oppfylte QC-kriteriene

26. juni 2024

Først lagt ut (Faktiske)

1. juli 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be available to other researchers.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere